

Efficacy and safety of baricitinib for the treatment of ho
(COV-BARRIER): a randomised, double-blind, parallel-g

Lancet Respiratory Medicine,the
9, 1407-1418

DOI: 10.1016/s2213-2600(21)00331-3

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	6.7	152
2	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1349-1351.	10.7	28
3	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	3.2	3
5	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. <i>Clinical Therapeutics</i> , 2021, 43, 1877-1893.e4.	2.5	6
6	Transient leukocytopenia following combination therapy for COVID-19. <i>Respiratory Investigation</i> , 2021, 60, 158-158.	1.8	3
7	Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 160, 243-260.	2.8	93
8	Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 99-104.	3.0	8
9	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
10	Myeloid cells in COVID-19 microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 372.	17.1	14
11	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	3.8	8
12	Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review. <i>Annals of Oncology</i> , 2022, 33, 158-168.	1.2	59
13	Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators. <i>Frontiers in Immunology</i> , 2021, 12, 768695.	4.8	7
14	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	3.8	0
15	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	4.1	21
17	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	5.6	9
18	Mortality in Solid Organ Transplant Recipients Hospitalized for Covid-19. <i>American Journal of Transplantation</i> , 2021, 22, 12.	4.7	4
19	Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. <i>Seminars in Immunology</i> , 2021, 55, 101522.	5.6	12
20	Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 773-779.	4.4	8

#	ARTICLE	IF	CITATIONS
21	Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease. <i>Internal Medicine</i> , 2022, 61, 585-589.	0.7	8
22	Nimotuzumab for COVID-19: case series. <i>Immunotherapy</i> , 2022, 14, 185-193.	2.0	6
25	Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 1523-1534.	5.0	28
26	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	5.1	10
27	JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. <i>Viruses</i> , 2021, 13, 2379.	3.3	38
28	Intravenous immunoglobulin therapy for COVID-19 ARDS. <i>Lancet Respiratory Medicine</i> , 2021, , .	10.7	5
29	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	4.3	41
30	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366.	2.4	4
31	Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.9	5
32	Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). <i>Drugs and Aging</i> , 2021, 38, 1067-1074.	2.7	11
33	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). <i>International Immunopharmacology</i> , 2022, 105, 108536.	3.8	32
34	A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112550.	5.6	26
35	A review of COVID-19 therapeutics in pregnancy and lactation. <i>Obstetric Medicine</i> , 2022, 15, 225-232.	1.1	13
36	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	4.4	20
38	Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective. <i>Molecules</i> , 2022, 27, 658.	3.8	24
39	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 792335.	3.7	3
40	Therapeutic role of immunomodulators during the COVID-19 pandemic – a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179.	2.0	9
41	Pre-Existing Lymphopenia Increases the Risk of Hospitalization and Death after SARS-CoV-2 Infection. <i>Infectious Disease Reports</i> , 2022, 14, 20-25.	3.1	6

#	ARTICLE	IF	CITATIONS
42	Pulmonary Aspects of COVID-19. Annual Review of Medicine, 2022, 73, 81-93.	12.2	8
43	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacology, 2022, 30, 23-49.	3.9	8
44	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nature Reviews Rheumatology, 2022, 18, 133-145.	8.0	193
45	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment “ Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	4.1	19
46	Elimination of Aicardiâ€“GoutiÃ”res syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication. Journal of Biological Chemistry, 2022, 298, 101635.	3.4	9
47	Multiple secondary outcome analyses: precise interpretation is important. Trials, 2022, 23, 27.	1.6	13
48	COVID-19 Drug Development. Journal of Microbiology and Biotechnology, 2022, 32, 1-5.	2.1	26
50	The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 800492.	2.6	20
51	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology, 2022, 149, 569-578.	2.9	3
52	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. Infectious Disease Clinics of North America, 2022, 36, 397-421.	5.1	7
53	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 327-336.	10.7	131
54	Pharmacologic Treatment and Management of Coronavirus Disease 2019. Infectious Disease Clinics of North America, 2022, 36, 349-364.	5.1	2
55	Baricitinib for patients with severe COVID-19â€”time to change the standard of care?. Lancet Respiratory Medicine,the, 2022, , .	10.7	6
56	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofac043.	0.9	4
57	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€”2 and Hyperinflammation in Pediatric COVIDâ€”19: Version 3. Arthritis and Rheumatology, 2022, 74, .	5.6	146
58	Deep learning for drug repurposing: Methods, databases, and applications. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2022, 12, .	14.6	48
59	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. Current Infectious Disease Reports, 2021, 23, 28.	3.0	5
60	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofab588.	0.9	7

#	ARTICLE	IF	CITATIONS
61	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	4.1	45
62	Pharmacological treatment of COVID-19: an opinion paper. Revista Espanola De Quimioterapia, 2022, 35, 115-130.	1.3	47
63	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resistance Updates, 2021, 59, 100794.	14.4	175
65	<i>In Silico</i> Evaluation for the Inhibitory Action of Curcumin Derivatives on the SARS-CoV-2 Proteins. Journal of Biosciences and Medicines, 2022, 10, 63-76.	0.2	0
66	Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinibâ€”a biological or synthetic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 68, 3-8.	0.7	1
67	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	5.8	6
68	Adrenomedullin Therapy in Moderate to Severe COVID-19. Biomedicines, 2022, 10, 533.	3.2	8
69	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. Journal of Personalized Medicine, 2022, 12, 349.	2.5	3
70	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. Vaccine, 2022, 40, 3484-3489.	3.8	6
71	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 2242.	4.1	17
74	Tocilizumab and COVID-19: Timing of Administration and Efficacy. Frontiers in Pharmacology, 2022, 13, 825749.	3.5	27
75	COVID-19 in the Critically Ill Patient. Infectious Disease Clinics of North America, 2022, 36, 365-377.	5.1	5
76	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports, 2022, 12, 2552.	3.3	23
77	MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with ARDS Outcome. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	2.9	1
78	Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. Frontiers in Pharmacology, 2022, 13, 840639.	3.5	17
79	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. Critical Care Clinics, 2022, , .	2.6	6
80	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling. Frontiers in Immunology, 2022, 13, 795315.	4.8	35
81	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. Critical Care Clinics, 2022, , .	2.6	3

#	ARTICLE	IF	CITATIONS
82	Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study. Journal of Medical Virology, 2022, , .	5.0	2
83	COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response. Acta Haematologica, 2022, 145, 297-309.	1.4	7
84	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infectious Diseases, 2022, 9, ofac104.	0.9	6
85	Oral surveillance and JAK inhibitor safety: the theory of relativity. Nature Reviews Rheumatology, 2022, 18, 301-304.	8.0	91
86	Synthesis of [² H ₅]baricitinib via [² H ₅]ethanesulfonyl chloride. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , .	1.0	2
87	Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT). Brazilian Journal of Infectious Diseases, 2022, 26, 102347.	0.6	3
88	Can anti-parasitic drugs help control COVID-19?. Future Virology, 2022, 17, 315-339.	1.8	5
89	Drug dosing in hospitalized obese patients with COVID-19. Critical Care, 2022, 26, 60.	5.8	3
90	Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study. Respiratory Investigation, 2022, 60, 418-424.	1.8	3
92	Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia. BMC Infectious Diseases, 2022, 22, 254.	2.9	3
93	Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. Infezioni in Medicina, 2022, 30, 11-21.	1.1	3
94	Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. Immunotherapy, 2022, 14, 521-530.	2.0	17
95	Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients. IScience, 2022, 25, 104075.	4.1	5
97	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. American Journal of Therapeutics, 2022, 29, e298-e304.	0.9	9
99	SARS-CoV-2 pathogenesis. Nature Reviews Microbiology, 2022, 20, 270-284.	28.6	404
101	COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report. Cureus, 2022, 14, e23755.	0.5	1
104	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. Medicina (Lithuania), 2022, 58, 513.	2.0	16
105	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. Pharmacological Research, 2022, 179, 106201.	7.1	23

#	ARTICLE	IF	CITATIONS
106	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. American Journal of Emergency Medicine, 2022, 56, 158-170.	1.6	13
107	Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study. Cureus, 2021, 13, e20620.	0.5	3
108	Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. Journal of Inflammation Research, 2021, Volume 14, 7225-7242.	3.5	15
109	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. Turkish Journal of Medical Sciences, 2021, 51, 3391-3404.	0.9	3
110	Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
111	Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2. Covid, 2021, 1, 757-774.	1.5	7
112	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	9.4	24
113	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. Pharmaceuticals, 2021, 14, 1256.	3.8	10
115	The infection risks of JAK inhibition. Expert Review of Clinical Immunology, 2022, 18, 253-261.	3.0	21
116	COVID-19 Infection in Children: Diagnosis and Management. Current Infectious Disease Reports, 2022, 24, 51-62.	3.0	25
117	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. Journal of Clinical Medicine, 2022, 11, 2279.	2.4	13
119	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. Process Biochemistry, 2022, 118, 154-170.	3.7	4
120	Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. Clinical Immunology, 2022, 238, 109016.	3.2	15
121	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). Wiener Klinische Wochenschrift, 2022, 134, 399-419.	1.9	1
122	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
123	Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science. Physiological Reviews, 2022, 102, 1569-1577.	28.8	9
124	SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia. Blood Advances, 2022, 6, 3840-3843.	5.2	7
125	What's JAK'ing Up the Risk of Cancer and Thromboembolism?. , 2022, 19, .		0

#	ARTICLE	IF	CITATIONS
126	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Stem Cells Translational Medicine</i> , 2022, 11, 688-703.	3.3	13
127	Therapeutics in the Treatment of COVID-19 for Children and Adolescents. <i>Pediatric Infection and Vaccine</i> , 2022, 29, 1.	0.4	2
128	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	1
129	Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4545.	4.1	11
130	External validation of the COVID-19 4C mortality score in an urban United States cohort. <i>American Journal of the Medical Sciences</i> , 2022, 364, 409-413.	1.1	5
131	Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. , 2022, 4, e0702.		10
132	What is the full potential of baricitinib in treating patients with COVID-19?. <i>Expert Review of Clinical Immunology</i> , 2022, , 1-5.	3.0	2
133	Year in Review 2021: Noteworthy Literature in Cardiothoracic Critical Care. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2022, , 108925322211006.	1.0	1
134	A Comprehensive Overview of Globally Approved JAK Inhibitors. <i>Pharmaceutics</i> , 2022, 14, 1001.	4.5	83
135	The Impact of Cytokines on Neutrophils's Phagocytosis and NET Formation during Sepsis's A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5076.	4.1	7
136	Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	5
137	The impact of COVID-19 on the pediatric solid organ transplant population. <i>Seminars in Pediatric Surgery</i> , 2022, 31, 151178.	1.1	8
138	Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. <i>Virology</i> , 2022, 572, 64-71.	2.4	12
139	Pearson's patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak. <i>IScience</i> , 2022, 25, 104415.	4.1	1
140	Addition of Baricitinib to COVID-19 Treatment Does Not Increase Bacterial Infection Compared to Standard Therapy: A Single-center Retrospective Study. <i>Internal Medicine</i> , 2022, 61, 2273-2279.	0.7	3
141	Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
142	Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients. <i>Panminerva Medica</i> , 0, , .	0.8	5
143	COVID-19-Current Therapeutical Approaches and Future Perspectives. <i>Processes</i> , 2022, 10, 1053.	2.8	1

#	ARTICLE	IF	CITATIONS
144	Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1344-1346.	1.7	2
145	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 888-899.	10.7	62
146	Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	22
147	Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. <i>ImmunoTargets and Therapy</i> , 0, Volume 11, 23-35.	5.8	3
148	Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2022, 9, 185-198.	2.0	3
149	Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26.	2.9	15
150	An Approach to the Treatment of Children With COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 654-662.	2.0	5
151	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. <i>EClinicalMedicine</i> , 2022, 49, 101493.	7.1	5
152	Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. <i>EClinicalMedicine</i> , 2022, 49, 101489.	7.1	52
153	Favipiravir in Early Symptomatic COVID-19, A Randomised Placebo-Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
154	Key Advances in Intensive Care and the Coronavirus Disease-19 Research and Practice Boost. <i>Journal of Clinical Medicine</i> , 2022, 11, 3370.	2.4	0
155	Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. <i>Antiviral Research</i> , 2022, 204, 105367.	4.1	17
156	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. <i>Vaccines</i> , 2022, 10, 951.	4.4	8
158	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	22
159	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	12.8	28
160	Levilimab and baricitinib prescribing experience in outpatient COVID-19 patientsâ€™ treatment. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 668-674.	0.8	3
161	Defining resistance and tolerance traits in Covid-19: towards a stratified medicine approach. <i>QJM - Monthly Journal of the Association of Physicians</i> , 0, , .	0.5	0
162	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	6.7	22

#	ARTICLE	IF	CITATIONS
163	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , 2022, 15, 739.	3.8	6
164	Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	3
165	Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents. <i>Clinical and Experimental Pediatrics</i> , 2022, 65, 377-386.	2.2	5
166	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	1.4	20
167	Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L372-L389.	2.9	9
168	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. <i>Annals of Epidemiology</i> , 2022, , .	1.9	2
169	Host genomics of SARS-CoV-2 infection. <i>European Journal of Human Genetics</i> , 0, , .	2.8	10
170	Current Effective Therapeutics in Management of COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 3838.	2.4	23
171	Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7702.	4.1	2
172	Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7365.	4.1	2
173	Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats. <i>Annals of Surgery</i> , 2023, 278, e137-e146.	4.2	6
174	Pyroptotic Patterns in Blood Leukocytes Predict Disease Severity and Outcome in COVID-19 Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
175	Management of Severe and Critical COVID-19 Infection with Immunotherapies. <i>Infectious Disease Clinics of North America</i> , 2022, , .	5.1	0
176	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	4.4	10
177	Oral antiviral treatments for COVID-19: opportunities and challenges. <i>Pharmacological Reports</i> , 2022, 74, 1255-1278.	3.3	31
178	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	3.7	46
181	Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 187-209.	2.4	5
182	Managing COVID-19 in pregnant women. <i>Breathe</i> , 2022, 18, 220019.	1.3	0

#	ARTICLE	IF	CITATIONS
183	(+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay. Scientific Reports, 2022, 12, .	3.3	12
184	Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. European Respiratory Journal, 2022, 60, 2200780.	6.7	15
185	Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. Journal of Infectious Diseases, 2022, 227, 23-34.	4.0	21
186	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. Open Forum Infectious Diseases, 2022, 9, .	0.9	6
187	Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality. Lancet, The, 2022, 400, 338-339.	13.7	4
188	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet, The, 2022, 400, 359-368.	13.7	146
189	Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clinical Infectious Diseases, 2023, 76, e116-e125.	5.8	13
190	Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2023, 29, 13-21.	6.0	19
191	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. Journal of Clinical Medicine, 2022, 11, 4464.	2.4	13
192	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. Open Forum Infectious Diseases, 2022, 9, .	0.9	15
193	Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice and Research in Clinical Haematology, 2022, 35, 101377.	1.7	3
194	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. Journal of Medical Virology, 2022, 94, 5702-5712.	5.0	7
195	An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry. Cytotherapy, 2022, 24, 1071-1073.	0.7	7
196	Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America, 2022, , .	2.5	1
197	Immunomodulatory therapies for COVID-19. Frontiers in Medicine, 0, 9, .	2.6	3
198	Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis. Expert Review of Respiratory Medicine, 2022, 16, 1109-1132.	2.5	4
199	Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-6.	1.9	4
200	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	3.8	47

#	ARTICLE	IF	CITATIONS
201	A review of clinical efficacy data supporting emergency use authorization for <scp>COVID</scp> â€19 therapeutics and lessons for future pandemics. Clinical and Translational Science, 0, , .	3.1	2
202	What Next? New Drugs, Old Drugs, and New Challenges in Choosing Treatments for Covid-19. , 2022, 1, .		0
203	Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials. Journal of Microbiology, Immunology and Infection, 2022, , .	3.1	1
204	Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study. PLoS ONE, 2022, 17, e0273340.	2.5	12
205	Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. Best Practice and Research in Clinical Haematology, 2022, 35, 101375.	1.7	0
206	Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels. Frontiers in Pediatrics, 0, 10, .	1.9	2
207	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Journal of Biomedical Science, 2022, 29, .	7.0	16
208	Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. Respiratory Medicine, 2022, 202, 106986.	2.9	6
209	COVID-19: Vaccines and therapeutics. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128987.	2.2	4
210	COVID-19 in patients with B cell immune deficiency. Journal of Immunological Methods, 2022, 510, 113351.	1.4	1
211	Treatment outcomes in Polish COVID-19 patients requiring hospitalisation in the intensive care unit: a single-centre retrospective study. Anaesthesiology Intensive Therapy, 2022, 54, 234-241.	1.0	0
212	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Frontiers in Medicine, 0, 9, .	2.6	4
213	A novel logical model of COVID-19 intracellular infection to support therapies development. PLoS Computational Biology, 2022, 18, e1010443.	3.2	0
214	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	2.4	15
215	Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. Current Medical Research and Opinion, 0, , 1-15.	1.9	10
216	Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?. Lancet Respiratory Medicine,the, 2022, 10, 1103-1104.	10.7	2
217	Safety and effectiveness of RBD-specific polyclonal equine F(abÂ²)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS ONE, 2022, 17, e0274796.	2.5	0
218	Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review. Cureus, 2022, , .	0.5	2

#	ARTICLE	IF	CITATIONS
219	Race, Ethnicity, and Health Disparities in US Children With COVID-19: A Review of the Evidence and Recommendations for the Future. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, S132-S140.	1.3	13
220	Management of COVID-19: A comprehensive and practical approach. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.8	1
221	The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro. <i>Biomedicines</i> , 2022, 10, 2324.	3.2	6
222	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). <i>Transplantation and Cellular Therapy</i> , 2022, 28, 810-821.	1.2	9
224	A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. <i>Advances in Therapy</i> , 2022, 39, 4910-4960.	2.9	28
225	Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19. , 2022, 4, e0760.		2
226	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. <i>ERJ Open Research</i> , 0, , 00236-2022.	2.6	2
227	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <i>Life</i> , 2022, 12, 1472.	2.4	6
229	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	4.1	4
230	Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. <i>Trials</i> , 2022, 23, .	1.6	1
231	Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. <i>Respiratory Research</i> , 2022, 23, .	3.6	12
232	Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort. <i>Infection</i> , 2023, 51, 851-858.	4.7	4
233	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	5.8	82
234	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	1.7	8
235	Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms. <i>Molecular Psychiatry</i> , 2022, 27, 5049-5061.	7.9	16
237	Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0275217.	2.5	16
238	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	1.5	0
239	Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia. <i>EBioMedicine</i> , 2022, 85, 104295.	6.1	5

#	ARTICLE	IF	CITATIONS
240	Targeting <scp>SARSâ€CoV</scp>â€2 infection through <scp>CARâ€T</scp>â€like bispecific T cell engagers incorporating <scp>ACE2</scp>. Clinical and Translational Immunology, 2022, 11, .	3.8	6
241	Japanese rapid/living recommendations on drug management for <scp>COVID</scp>â€19: updated guidelines (July 2022). Acute Medicine & Surgery, 2022, 9, .	1.2	6
242	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211327.	2.6	3
243	Harnessing AI and Genomics to Accelerate Drug Discovery. Future of Business and Finance, 2022, , 89-106.	0.4	1
244	Pin-Pointing the Key Hubs in the IFN-Î³ Pathway Responding to SARS-CoV-2 Infection. Viruses, 2022, 14, 2180.	3.3	3
245	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. Biomedicines, 2022, 10, 2620.	3.2	6
246	Predictors of clinical evolution of SARSâ€CoVâ€2 infection in hematological patients: A systematic review and metaâ€analysis. Hematological Oncology, 2023, 41, 16-25.	1.7	6
247	JAK: Not Just Another Kinase. Molecular Cancer Therapeutics, 2022, 21, 1757-1764.	4.1	23
248	Baricitinib in the Treatment of COVID-19. , 0, , .		0
249	Considerations for management of patients with diabetes mellitus and acute COVID-19. World Journal of Diabetes, 0, 13, 802-808.	3.5	0
250	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. Biomedicines, 2022, 10, 2628.	3.2	1
251	Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	3.5	7
252	COVID-19 and HSCT (Hematopoietic stem cell transplant). Best Practice and Research in Clinical Haematology, 2022, 35, 101399.	1.7	8
253	Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. International Journal of Infectious Diseases, 2022, 125, 233-240.	3.3	4
254	Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation. Biomedicines, 2022, 10, 2525.	3.2	10
255	Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?. International Journal of Molecular Sciences, 2022, 23, 12260.	4.1	2
256	Fewer <scp>COVIDâ€19</scp> Neurological Complications with Dexamethasone and Remdesivir. Annals of Neurology, 2023, 93, 88-102.	5.3	10
257	Randomized Phase 3 Trial of Ruxolitinib for COVID-19â€Associated Acute Respiratory Distress Syndrome*. Critical Care Medicine, 2022, 50, 1701-1713.	0.9	16

#	ARTICLE	IF	CITATIONS
258	Treatment of severe COVID-19: an evolving paradigm. Expert Opinion on Pharmacotherapy, 2022, 23, 1887-1891.	1.8	5
259	Immune Modulation in Sepsis, ARDS, and Covid-19 “ The Road Traveled and the Road Ahead. , 2022, 1, .		6
260	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Frontiers in Pharmacology, 0, 13, .	3.5	8
261	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	9.6	67
262	COVID-19 Therapeutics and Considerations for Pregnancy. Obstetrics and Gynecology Clinics of North America, 2022, , .	1.9	0
263	Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clinical Microbiology and Infection, 2023, 29, 372-378.	6.0	24
264	Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*. Critical Care Medicine, 2022, 50, 1788-1798.	0.9	13
265	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life, 2022, 12, 1758.	2.4	9
266	Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine, 2022, 54, 101703.	7.1	23
267	Cytokine Release Syndrome and Sepsis. Infectious Disease Clinics of North America, 2022, 36, 735-748.	5.1	4
268	AI for Drug Repurposing in the Pandemic Response. , 2022, , 59-84.		0
269	Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?. Asian Journal of University Education, 0, 8, 21-24.	0.3	0
272	Reply to Yan. Clinical Infectious Diseases, 0, , .	5.8	0
273	Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?. Biomedicines, 2022, 10, 2815.	3.2	3
274	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	1.3	0
275	Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. International Journal of Molecular Sciences, 2022, 23, 13478.	4.1	3
276	A Rationale and Approach to the Development of Specific Treatments for HIV Associated Neurocognitive Impairment. Microorganisms, 2022, 10, 2244.	3.6	2
278	A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney International, 2023, 103, 514-528.	5.2	11

#	ARTICLE	IF	CITATIONS
279	Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. <i>Platelets</i> , 2023, 34, .	2.3	13
280	Design, Synthesis, and Biological Evaluation of Novel Ruxolitinib and Baricitinib Analogues for Potential Use Against COVID-19. <i>Chemical Biology and Drug Design</i> , 0, , .	3.2	2
281	Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials*. <i>Critical Care Medicine</i> , 2022, 50, 1821-1828.	0.9	1
282	A review on global perspective of illicit drug utilization and substance use disorders. <i>Archives of Medicine and Health Sciences</i> , 2022, 10, 266.	0.1	0
283	RECOVERY Trial Data on Baricitinib in Patients Hospitalized with Coronavirus Disease 2019. , 2022, 1, 10.		0
284	Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
285	Prevalence of bacterial co infections among Covid 19 patients in wasit province. <i>International Journal of Health Sciences</i> , 0, , 48971-48984.	0.1	0
286	Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review. <i>HRB Open Research</i> , 0, 5, 77.	0.6	1
287	Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
288	Infliximab as a potential treatment for COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2023, 21, 1-5.	4.4	4
289	Immunomodulatory agents for COVID-19 pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	2.1	1
290	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15027.	4.1	2
291	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1716-1727.	3.9	2
292	Growth Arrest of Alveolar Cells in Response to Cytokines from Spike S1-Activated Macrophages: Role of IFN- γ . <i>Biomedicines</i> , 2022, 10, 3085.	3.2	3
293	Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2242918.	5.9	2
294	Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies. <i>Pharmaceutics</i> , 2022, 14, 2714.	4.5	5
295	A leap towards personalised therapy of acute lung injury. <i>European Respiratory Journal</i> , 2022, 60, 2201808.	6.7	1
296	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	42

#	ARTICLE	IF	CITATIONS
297	Tale of the Titters: Serologic Testing for SARS-CoV-2 -Yes, No, and Maybe, with Clinical Examples from the IDSA Diagnostics Committee. Open Forum Infectious Diseases, 0, , .	0.9	1
299	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer, 2023, 181, 102-118.	2.8	2
300	Assessment of the pneumonia severity score in community-acquired and nursing and healthcare-associated pneumonia due to COVID-19. Journal of Infection and Chemotherapy, 2023, 29, 437-442.	1.7	2
301	Management of Coronavirus Disease-2019 Infection in Pregnancy. Emergency Medicine Clinics of North America, 2023, 41, 307-322.	1.2	0
302	Criteria for hyperinflammation developing in coronavirus diseaseâ€19: analysis of two cohorts from different periods of the pandemic. Arthritis and Rheumatology, 0, , .	5.6	1
303	Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. European Respiratory Journal, 0, , 2202008.	6.7	0
304	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. Health Research Policy and Systems, 2022, 20, .	2.8	3
305	COVID-19 drug-induced liver injury: A recent update of the literature. World Journal of Gastroenterology, 0, 28, 6314-6327.	3.3	5
306	Immune-based therapy for hospitalized patients with COVID-19 and risk of secondary infections: A systematic review and meta-analysis. Open Forum Infectious Diseases, 0, , .	0.9	1
307	Lymphopenia in sepsisâ€an acquired immunodeficiency?. Immunology and Cell Biology, 2023, 101, 535-544.	2.3	12
308	Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Frontiers in Medicine, 0, 9, .	2.6	19
309	Data-driven drug discovery for drug repurposing. Folia Pharmacologica Japonica, 2023, 158, 10-14.	0.2	0
310	Baricitinib or imatinib in hospitalized COVIDâ€19 patients: Results from COVINIB, an exploratory randomized clinical trial. Journal of Medical Virology, 2023, 95, .	5.0	4
311	A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. Inflammation and Regeneration, 2023, 43, .	3.7	8
313	Innate immune evasion strategies of SARS-CoV-2. Nature Reviews Microbiology, 0, , .	28.6	31
314	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Critical Care, 2023, 27, .	5.8	12
315	Sepsis presentation and pathophysiology. , 2023, , 489-501.		0
316	Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients. Cell Reports Medicine, 2023, 4, 100935.	6.5	2

#	ARTICLE	IF	CITATIONS
317	Innate immune responses in COVID-19. , 2023, , 63-128.		0
318	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. , 2023, , 99-139.		1
319	The Influence of Sex on Characteristics and Outcomes of Coronavirus-19 Patients: A Retrospective Cohort Study. Journal of Clinical Medicine, 2023, 12, 1118.	2.4	0
320	Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence. Dermatitis, 0, , .	1.6	0
321	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	5.9	0
322	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS ONE, 2023, 18, e0274243.	2.5	0
323	Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia. Medicina Clínica (English Edition), 2023, , .	0.2	0
324	Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*. Critical Care Medicine, 2023, 51, 337-346.	0.9	11
325	A fatal case of COVID-19-associated meningoencephalitis in a patient coinfectd with influenza A. Revista Do Instituto De Medicina Tropical De Sao Paulo, 0, 65, .	1.1	1
326	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. Thorax, 2023, 78, 816-824.	5.6	3
327	Down-regulation of KLF2 in lung fibroblasts is linked with COVID-19 immunofibrosis and restored by combined inhibition of NETs, JAK-1/2 and IL-6 signaling. Clinical Immunology, 2023, 247, 109240.	3.2	7
328	SARS-CoV-2 Genome Variations in Viral Shedding of an Immunocompromised Patient with Non-Hodgkinâ€™s Lymphoma. Viruses, 2023, 15, 377.	3.3	2
329	Respiratory viruses: New frontiersâ€™a Keystone Symposia report. Annals of the New York Academy of Sciences, 2023, 1522, 60-73.	3.8	0
330	Using risk factors and markers to predict bacterial respiratory co-/superinfections in COVID-19 patients: is the antibiotic stewardâ€™s toolbox full or empty?. Acta Clinica Belgica, 2023, 78, 418-430.	1.2	1
331	A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. Vaccines, 2023, 11, 332.	4.4	4
332	Effect of extracorporeal hemoabsorption in critically ill patients with COVID-19: A narrative review. Frontiers in Immunology, 0, 14, .	4.8	2
333	COVID-19 therapy and vaccination: a clinical narrative review. Drugs in Context, 0, 12, 1-11.	2.2	10
334	Nucleoside Analogs That Inhibit SARS-CoV-2 Replication by Blocking Interaction of Virus Polymerase with RNA. International Journal of Molecular Sciences, 2023, 24, 3361.	4.1	3

#	ARTICLE	IF	CITATIONS
335	Therapeutic options in COVID-19. , 2023, , 647-672.		0
336	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. Infection, 2023, 51, 1033-1049.	4.7	8
337	Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome. PLoS ONE, 2023, 18, e0280677.	2.5	2
338	Current and Emerging Therapies for COVID-19 in Lung Transplantation. Current Pulmonology Reports, 2023, 12, 23-35.	1.3	1
339	Insights into COVID-19-associated critical illness: a narrative review. Annals of Translational Medicine, 2023, 11, 220-220.	1.7	2
340	Severe COVID-19-associated hyperinflammatory syndrome versus classic hemophagocytic lymphohistiocytosis: similarities, differences, and the way forward. Journal of Investigative Medicine, 2023, 71, 244-253.	1.6	0
341	Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity. Journal of Pharmacy Practice, 0, , 089719002311589.	1.0	1
342	Strongyloides and COVID-19: Challenges and Opportunities for Future Research. Tropical Medicine and Infectious Disease, 2023, 8, 127.	2.3	2
343	Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. Viruses, 2023, 15, 568.	3.3	2
344	Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study. International Journal of General Medicine, 0, Volume 16, 657-672.	1.8	2
345	Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*. Critical Care Medicine, 2023, 51, 413-415.	0.9	0
347	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	3.2	28
348	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. International Journal of Molecular Sciences, 2023, 24, 4401.	4.1	4
349	Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open, 2023, 13, e067910.	1.9	7
350	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. Inflammopharmacology, 2023, 31, 633-651.	3.9	9
353	Risk factors of pneumothorax and pneumomediastinum in COVID-19: a matched caseâ€“control study. BMC Infectious Diseases, 2023, 23, .	2.9	1
354	5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". The Journal of the Japanese Society of Internal Medicine, 2022, 111, 578-584.	0.0	0
355	Emerging role of baricitinib in dermatology practice: All we need to know!. Indian Dermatology Online Journal, 2023, 14, 153.	0.5	0

#	ARTICLE	IF	CITATIONS
356	Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib”Retrospective Single-Center Study. Life, 2023, 13, 755.	2.4	1
357	Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review. Frontiers in Medicine, 0, 10, .	2.6	3
358	Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. Cureus, 2023, , .	0.5	0
359	Feasibility Study of Cord Tissue Derived Mesenchymal Stromal Cells in COVID-19-Related Acute Respiratory Distress Syndrome. Stem Cells Translational Medicine, 2023, 12, 185-193.	3.3	3
360	COVID-19 and the Genetics of Inflammation. Critical Care Medicine, 2023, 51, 817-825.	0.9	3
361	Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. Frontiers in Pharmacology, 0, 14, .	3.5	10
362	COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices. Viruses, 2023, 15, 787.	3.3	5
363	Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2023, 37, 475-493.	5.1	1
366	Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins. Biomolecules, 2023, 13, 578.	4.0	0
367	Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study. PLoS ONE, 2023, 18, e0283529.	2.5	0
368	The impact of the COVID-19 pandemic on ASLE. Modern Rheumatology, 2024, 34, 247-264.	1.8	1
369	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. Journal of Inflammation, 2023, 20, .	3.4	2
370	Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World Journal of Clinical Cases, 0, 11, 2168-2180.	0.8	2
372	Biomimetic SARS-CoV-2 Spike Protein Nanoparticles. Biomacromolecules, 2023, 24, 2030-2041.	5.4	1
373	Treatment options for patients with severe COVID-19. Global Health & Medicine, 2023, 5, 99-105.	1.4	1
374	Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching. F1000Research, 0, 12, 398.	1.6	1
375	A Rare Side Effect of COVID-19 Treatment: Avascular Femoral Necrosis. , 0, , 33-37.		0
376	Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan. Respiratory Investigation, 2023, 61, 438-444.	1.8	0

#	ARTICLE	IF	CITATIONS
377	Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections. Open Forum Infectious Diseases, 2023, 10, .	0.9	2
378	Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 2023, 22, 449-475.	46.4	112
379	Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review. Infectious Diseases of Poverty, 2023, 12, .	3.7	2
380	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. European Journal of Clinical Pharmacology, 2023, 79, 723-751.	1.9	7
381	Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	35
382	Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respiratory Medicine, the, 2023, 11, 709-725.	10.7	19
383	Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection. Southern Medical Journal, 2023, 116, 427-433.	0.7	2
384	Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality. Thorax, 2023, 78, 912-921.	5.6	6
385	Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19. BioMed, 2023, 3, 236-245.	1.1	0
386	Primary-Sjögren's-Syndrome-Related Interstitial Lung Disease: A Clinical Review Discussing Current Controversies. Journal of Clinical Medicine, 2023, 12, 3428.	2.4	5
387	JAK-STAT pathway inhibitors in dermatology. Anais Brasileiros De Dermatologia, 2023, 98, 656-677.	1.1	12
388	SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?. International Journal of Molecular Sciences, 2023, 24, 9353.	4.1	3
390	Nangibotide for precision immunomodulation in septic shock and COVID-19. Lancet Respiratory Medicine, the, 2023, 11, 855-857.	10.7	2
391	Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19. Recent Advances in Inflammation & Allergy Drug Discovery, 2023, 17, .	0.8	1
392	Investigation on the binding behavior of human Î±1-acid glycoprotein with Janus Kinase inhibitor baricitinib: Multi-spectroscopic and molecular simulation methodologies. International Journal of Biological Macromolecules, 2023, 244, 125096.	7.5	1
393	Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients with COVID-19 Using Nationwide Real-World Data: An Observational Matched Cohort Study from The Japan COVID-19 Task Force. Open Forum Infectious Diseases, 0, , .	0.9	0
394	Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study. Journal of Clinical Medicine, 2023, 12, 3928.	2.4	1
395	COVID-19 and Hematopoietic Stem Cell Transplantation. , 2023, , 177-192.		0

#	ARTICLE	IF	CITATIONS
396	Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial. <i>Critical Care</i> , 2023, 27, .	5.8	3
397	Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 4138-4146.	5.4	1
398	Exploration of the optimal GS-441524 trough concentration for treating COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2023, 62, 106892.	2.5	2
399	COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases. <i>Respiratory Investigation</i> , 2023, 61, 601-617.	1.8	2
400	Pharmacokinetics of baricitinib in critically ill COVID-19 patients. <i>Clinical Biochemistry</i> , 2023, , 110601.	1.9	0
401	An update on drug-drug interactions for care of the acutely ill in the era of COVID-19. <i>American Journal of Health-System Pharmacy</i> , 0, , .	1.0	0
402	Unmasking the enigma: An in-depth analysis of COVID-19 impact on the pediatric population. <i>Journal of Infection and Public Health</i> , 2023, 16, 1346-1360.	4.1	1
403	Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19. <i>Clinical Immunology</i> , 2023, 251, 109628.	3.2	1
404	The use of janus kinase inhibitors anti-interleukin therapy in the Russian Federation with COVID-19: pharmacoepidemiological study. <i>HIV Infection and Immunosuppressive Disorders</i> , 2023, 15, 41-49.	0.3	0
406	Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
407	Genetic Associations with Coronavirus Susceptibility and Disease Severity. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 119-140.	1.6	1
408	Coronavirus disease 2019 and acute cerebrovascular events: a comprehensive overview. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
410	Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 328.	7.4	15
411	Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2023, 62, 106920.	2.5	0
412	Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury. <i>Cytokine and Growth Factor Reviews</i> , 2023, , .	7.2	0
413	Alpha and Delta variants and vaccination effectiveness against severity in COVID-19 inpatients based on medical claims in Japan. <i>GHM Open</i> , 2023, 3, 28-36.	0.6	1
414	Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness. <i>Lancet Respiratory Medicine</i> , 2023, 11, 726-738.	10.7	9
415	Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise. <i>Contemporary Clinical Trials Communications</i> , 2023, 35, 101190.	1.1	0

#	ARTICLE	IF	CITATIONS
416	Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001627.	3.0	1
417	Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020â€“2022). <i>Viruses</i> , 2023, 15, 1616.	3.3	2
418	COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, .	3.2	1
419	Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	1
420	COVID-19 Treatments: Then and Now. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 3321-3333.	3.8	1
421	Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2023, 22, .	3.8	2
422	Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	0
423	The Penn Medicine COVID-19 Therapeutics Committeeâ€™Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	0
424	Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2023, 37, 100788.	2.9	0
425	Adverse Effects of Tocilizumab Versus Baricitinib in Severe COVID-19. <i>Critical Care Medicine</i> , 2023, 51, e184-e185.	0.9	0
426	JAK inhibitors and black box warnings: what is the future for JAK inhibitors?. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 1385-1397.	3.0	2
427	Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. <i>Transplant Infectious Disease</i> , 2023, 25, .	1.7	1
428	Baricitinib versus tocilizumab in critically ill <scp>COVID</scp>-19 patients: A retrospective cohort study. <i>Pharmacotherapy</i> , 2024, 44, 28-38.	2.6	0
429	Comparative analysis of CRP as a biomarker of the inflammatory response intensity among common viral infections affecting the lungs: COVID-19 versus influenza A, influenza B and respiratory syncytial virus. <i>Clinical and Experimental Medicine</i> , 2023, 23, 5307-5313.	3.6	1
430	FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial. <i>Critical Care</i> , 2023, 27, .	5.8	0
431	Targeting SARS-CoV-2 Non-Structural Proteins. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13002.	4.1	5
432	COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine. <i>Reports</i> , 2023, 6, 45.	0.5	0
433	Missed Opportunities for Antifungal Stewardship during the COVID-19 Era. <i>Antibiotics</i> , 2023, 12, 1352.	3.7	1

#	ARTICLE	IF	CITATIONS
434	Rationale for combined therapies in severe-to-critical COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
435	Risk factors for mortality in severe COVID-19: Exploring the interplay of immunomodulatory therapy and coinfection. <i>Anaesthesia and Intensive Care</i> , 0, , .	0.7	0
436	Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward. <i>Paediatric Drugs</i> , 2023, 25, 635-647.	3.1	1
437	Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
438	Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis. <i>Translational Neurodegeneration</i> , 2023, 12, .	8.0	1
439	Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib. <i>Journal of Clinical Medicine</i> , 2023, 12, 6690.	2.4	4
440	The role of SARS-CoV-2-mediated NF- κ B activation in COVID-19 patients. <i>Hypertension Research</i> , 2024, 47, 375-384.	2.7	2
443	Baricitinib protects mice from sepsis-induced cardiac dysfunction and multiple-organ failure. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
444	Treatments for COVID-19. <i>Annual Review of Medicine</i> , 2024, 75, 145-157.	12.2	5
445	Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review. , 2023, 2, e000352.		1
446	Managing hospitalized patients with COVID-19. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2023, 36, 16-20.	0.3	0
447	The power and pressure placed on clinicians and guideline panels. <i>Lancet Infectious Diseases</i> , The, 2024, 24, 3-4.	9.1	0
448	High-Flow Nasal Cannula oxygen therapy in COVID-19: retrospective analysis of clinical outcomes â€“ single center experience. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
449	Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study. <i>Infectious Diseases and Therapy</i> , 2023, 12, 2471-2484.	4.0	0
451	Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. <i>Health Technology Assessment</i> , 0, , 1-92.	2.8	0
452	Post-COVID-19 pulmonary fibrosis: An ongoing concern. <i>Annals of Thoracic Medicine</i> , 2023, 18, 173-181.	1.8	1
453	Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	2
454	Enpatoran in <scp>COVID</scp>â€“19 pneumonia: Safety and efficacy results from a phase <scp>II</scp> randomized trial. <i>Clinical and Translational Science</i> , 2023, 16, 2640-2653.	3.1	1

#	ARTICLE	IF	CITATIONS
455	Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials. <i>Clinical Epidemiology</i> , 0, Volume 15, 1041-1053.	3.0	1
456	Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 139-160.	0.9	5
457	From Emergence to Endemicity: A Comprehensive Review of COVID-19. <i>Cureus</i> , 2023, , .	0.5	1
458	Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	1
459	Inhibition of T-cell activity in alopecia areata: recent developments and new directions. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
460	Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
461	Treatment of severe COVID-19: a role for JAK and complement inhibitors?. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 1036-1037.	10.7	2
462	Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	2.3	0
463	JAK1 promotes HDV replication and is a potential target for antiviral therapy. <i>Journal of Hepatology</i> , 2024, 80, 220-231.	3.7	2
464	Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients. <i>Nefrologia</i> , 2023, 43, 531-545.	0.4	0
465	Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 1064-1074.	10.7	4
467	The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors. <i>Journal of the Royal Society of Medicine</i> , 2024, 117, 57-68.	2.0	1
468	Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection. <i>Journal of Virology</i> , 0, , .	3.4	0
469	SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19. <i>Heliyon</i> , 2023, 9, e21893.	3.2	1
471	Acute Respiratory Failure From Early Pandemic COVID-19. , 2024, 2, 100030.		1
472	Nosocomial <scp>COVIDâ€19</scp> infection in the era of vaccination and antiviral therapy. <i>Internal Medicine Journal</i> , 0, , .	0.8	0
473	Baricitinib and Î²-Cell Function in Patients with New-Onset Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2023, 389, 2140-2150.	27.0	14
475	Inhaled beclomethasone in the treatment of early COVID-19: a double-blind, placebo-controlled, randomised, hospital-based trial in Sri Lanka. <i>BMJ Open</i> , 2023, 13, e075803.	1.9	0

#	ARTICLE	IF	CITATIONS
476	Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.	28.6	1
477	Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. <i>Lancet Respiratory Medicine</i> , 2023, , .	10.7	6
478	The Therapy of SARS-CoV-2 Infection in Children. <i>Journal of Clinical Medicine</i> , 2024, 13, 120.	2.4	0
479	An Update on SARS-CoV-2 Clinical Trial Results“What We Can Learn for the Next Pandemic. <i>International Journal of Molecular Sciences</i> , 2024, 25, 354.	4.1	1
480	Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial. <i>PLoS ONE</i> , 2023, 18, e0295838.	2.5	0
481	Pharmacologic Treatments in Acute Respiratory Failure. <i>Critical Care Clinics</i> , 2024, 40, 275-289.	2.6	0
482	Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era. <i>Nano Convergence</i> , 2024, 11, .	12.1	1
483	Treatment of COVID-19: Antivirals, Antibody Products, Immunomodulators, Antithrombotic Therapy, and Supplements. , 2023, 3, 91-100.		0
484	Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial. <i>Open Forum Infectious Diseases</i> , 2024, 11, .	0.9	0
485	Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. <i>Clinical Microbiology and Infection</i> , 2024, 30, 611-618.	6.0	1
486	Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching. <i>F1000Research</i> , 0, 12, 398.	1.6	0
487	Baricitinib statistically significantly reduced COVID-19-related mortality: a systematic review and meta-analysis of five phase III randomized, blinded and placebo-controlled clinical trials. <i>Biology Methods and Protocols</i> , 2024, 9, .	2.2	0
489	Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
490	Investigational pharmacological agents for the treatment of ARDS. <i>Expert Opinion on Investigational Drugs</i> , 2024, 33, 243-277.	4.1	0
491	CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
492	Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients. <i>Clinical Proteomics</i> , 2024, 21, .	2.1	0
493	Management of SARS-CoV-2 and Persistent Viral Detection in Solid Organ Transplant Recipients. <i>Current Pulmonology Reports</i> , 2024, 13, 26-37.	1.3	0
494	Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID). <i>Pneumonia (Nathan Qld)</i> , 2024, 16, .	6.1	0

#	ARTICLE	IF	CITATIONS
495	A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Annals of Internal Medicine, 2024, 177, 343-352.	3.9	0
496	Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19. Frontiers in Immunology, 0, 15, .	4.8	0
497	Prediction of Binding Pose and Affinity of Nelfinavir, a SARS-CoV-2 Main Protease Repositioned Drug, by Combining Docking, Molecular Dynamics, and Fragment Molecular Orbital Calculations. Journal of Physical Chemistry B, 2024, 128, 2249-2265.	2.6	0
498	How Much More Efficient Are Adaptive Platform Trials Than Multiple Standâ€Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic. Clinical Pharmacology and Therapeutics, 0, , .	4.7	0